Form 4: RA Capital Management Increases Stake in Janux Therapeutics

RA Capital Management and related entities have increased their holdings in Janux Therapeutics through a series of open market purchases.

Summary

• RA Capital Management, L.P., along with related entities including RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P., have increased their ownership stake in Janux Therapeutics, Inc.
• Between March 5, 2025, and March 7, 2025, these entities purchased shares of Janux Therapeutics common stock in multiple transactions.
• The purchases were made at varying prices, ranging from approximately $29.90 to $31.50 per share.
• The total number of shares beneficially owned by RA Capital Management and related entities after these transactions is 10,141,287 shares held by the Fund and 1,048,406 shares held by the Nexus Fund II.
• Several individuals associated with RA Capital Management, including Peter Kolchinsky and Rajeev Shah, disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
• Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The increased investment by RA Capital Management could be seen as a positive signal, but the document itself is simply a regulatory filing of transactions.

Positives

• Increased investment by a major shareholder like RA Capital Management could signal confidence in Janux Therapeutics' prospects.

Industry Context

Form 4 filings are standard disclosures for significant shareholders, providing transparency into their trading activities. RA Capital Management is a well-known healthcare-focused investment firm, so their increased stake in Janux Therapeutics is noteworthy within the biotech investment community.

Comparison to Industry Standards

• RA Capital's investment strategy often involves taking significant positions in biotech companies, similar to other firms like OrbiMed Advisors and Baker Bros.
• The reported transactions are typical for institutional investors adjusting their holdings, and the disclosure aligns with SEC regulations for insider trading.

Stakeholder Impact

• The increased stake by RA Capital Management could positively influence shareholder confidence.

Key Dates